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Abstract
The mammalian target of rapamycin (mTOR) pathway is commonly activated in human cancers. The activity of mTOR
complex 1 (mTORC1) signaling is supported by the intracellular positioning of cellular compartments and vesicle
trafﬁcking, regulated by Rab GTPases. Here we showed that tuftelin 1 (TUFT1) was involved in the activation of
mTORC1 through modulating the Rab GTPase-regulated process. TUFT1 promoted tumor growth and metastasis.
Consistently, the expression of TUFT1 correlated with poor prognosis in lung, breast and gastric cancers.
Mechanistically, TUFT1 physically interacted with RABGAP1, thereby modulating intracellular lysosomal positioning and
vesicular trafﬁcking, and promoted mTORC1 signaling. In addition, expression of TUFT1 predicted sensitivity to
perifosine, an alkylphospholipid that alters the composition of lipid rafts. Perifosine treatment altered the positioning
and trafﬁcking of cellular compartments to inhibit mTORC1. Our observations indicate that TUFT1 is a key regulator of
the mTORC1 pathway and suggest that it is a promising therapeutic target or a biomarker for tumor progression.
Introduction
Regulation of intracellular compartment positioning
and vesicular trafﬁcking is essential for multiple biological
processes. Rab GTPases play critical roles as master reg-
ulators in cellular compartment positioning and vesicular
trafﬁcking1, 2. Over 60 RAB genes are encoded in the
human genome. Rab GTPases function as molecular
switches through their guanine nucleotide-binding status,
like the other Ras superfamily proteins. Many Rab pro-
teins are involved in cancer progression. For example,
increased abundance of Rab5A and expression of RAB7
occur in breast and lung cancer, respectively3, 4. RAB25 is
frequently ampliﬁed in breast and ovarian cancers and is
associated with poor prognosis5. However, the mechan-
isms by which dysregulated expression of Rab GTPases
contribute to tumorigenesis are poorly understood.
mTOR is a serine-threonine kinase that regulates cell
growth and survival; its deregulation is frequently
observed in human diseases, including type II diabetes
and cancer6, 7. mTOR is an attractive target for cancer
therapy, because the activation of phosphoinositide 3-
kinase (PI3K)-mTOR signaling promotes resistance to
conventional chemotherapies. mTOR forms two distinct
multiprotein complexes, complex 1 (mTORC1) and
complex 2 (mTORC2)8–10. In response to various phy-
siological factors, including growth factors, energy status
and amino acids, mTORC1 regulates multiple types of
cellular processes, including mRNA translation. The small
GTPase Rheb directly regulates mTORC1 activation
downstream of the PI3K and AMP-activated protein
kinase (AMPK) pathways and is activated by growth fac-
tors and glucose11. Amino acid-dependent mTORC1
activation requires four Rag family small GTPases: RagA,
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Fig. 1 TUFT1, a TGF-β-induced poor cancer prognostic factor, regulates tumor cell morphology, motility and proliferation. a Kaplan Meier
plot of overall survival stratiﬁed by TUFT1 expression using the KM-Plotter version 2015 of lung cancer meta-analysis data. In the left panel, probability
of overall survival of 1,926 patients split by median was displayed. In the right panel, stage I lung adenocarcinoma cases were subjected to the same
analysis. b qRT-PCR analysis of A549 cells to evaluate the responsiveness of TUFT1 mRNA expression to TGF-β (1 ng/mL) for 48 h. Results are means ±
s.e.m. of three independent experiments. c A549 cells transfected with the indicated siRNAs were treated for 48 h with TGF-β and stained with
ﬂuorescein-conjugated phalloidin to visualize actin stress ﬁbers. Images are representative of three independent experiments. Scale bar, 20 μm. d
A549 cells expressing indicated shRNAs and proteins were seeded in upper chambers with collagen-coated pores. Exogenously expressed proteins
are shown in parentheses. Cells that migrated through the membrane were counted. Representative ﬁelds are shown (left). Results are means ± s.e.m.
of six independent experiments (right). *P < 0.05; **P < 0.01; ***P < 0.001. e A549 cells expressing indicated shRNAs and proteins (5 × 104 cells) were
seeded and cultured for 48 h. The live cell number of A549 cells was assessed by trypan blue staining. Exogenously expressed proteins are shown in
parentheses. Data are presented as mean ± s.d. of three independent experiments. *P < 0.05; **P < 0.01. f A total of 1×106 infected A549 cells
expressing indicated shRNAs and proteins were xenografted and the volumes of the resulting tumors were measured. Exogenously expressed
proteins are shown in parentheses. The result shows the combined data of the two independent experiments. Data are shown as mean ± s.e.m. N = 9
(shTUFT1#2 (GFP)) or 10 (others) mice per group. *P < 0.05; **P < 0.01. g Metastatic cells were analyzed by in vivo imaging in nude mice injected with
MDA-231-D cells (1×105 cells) expressing the indicated shRNAs. The horizontal bars indicate the mean for each group. N = 15 mice for the shNC
group, N = 11 mice for the shTUFT1#1 group. The experiment was repeated with similar results, and representative images are shown (left). Dot plot
for number of lesions per mouse from the two independent experiments is shown in the right panel. ph/s: photon counts per second. h A549 cells
were transfected with the indicated siRNAs and treated with or without TGF-β for 48 h. Total amounts of RhoA were detected by immunoblotting.
Results are representative of three independent experiments. mRNA expression was quantiﬁed by qRT-PCR (bottom panel). Results are means ± s.e.m.
of three independent experiments. i Cells were cultured as in h. Cell lysates were analyzed by immunoblotting. Results are representative of two
independent experiments. mRNA expression of cyclin D1 (CCND1) was quantiﬁed by qRT-PCR (bottom panel). Results are means ± s.e.m. of three
independent experiments.
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RagB, RagC, and RagD12, 13. The nucleotide-binding states
of Rag complexes control the intracellular relocalization
of mTORC1 from the cytosol to the lysosomal surface in
response to amino acids. mTORC1 is then directly acti-
vated by GTP-bound Rheb GTPase on the surface of the
lysosome14.
Intracellular compartment positioning and vesicular
trafﬁcking determine the activity of mTORC1 signaling, in
particular, through lysosomal localization15, 16. In a cel-
lular model of Huntington’s disease, perinuclear accu-
mulation of lysosomes and mTORC1 hyper-activation are
observed. In addition, overexpression of GDP- or GTP-
bound mutants of several Rab GTPases strongly inhibits
mTORC1 activation17. These results indicate that cycling
and cellular trafﬁcking of Rab GTPases are required for
mTORC1 activation. However, the regulatory proteins
that mediate the vesicular trafﬁcking in the context of
mTORC1 remain to be characterized.
Tuftelin 1 (TUFT1) is evolutionally conserved and is
thought to play a role in the mineralization of dental
enamel, which covers vertebrate teeth18, 19. However,
TUFT1 is also found in non-mineralizing tissues and in
various tumors20, 21. In the pheochromocytoma cell line
PC12, TUFT1 abundance is increased by hypoxia in a
hypoxia-inducible factor-1α-dependent manner22, 23.
TUFT1 is therefore considered to be involved in cancer,
but its physiological functions in normal and cancerous
tissues remain uncharacterized.
Here, we demonstrate that TUFT1 is a key regulator of
the mTORC1 signaling pathway. TUFT1 deﬁciency
caused dispersion of the transport vesicles and lysosomes,
and inhibition of mTORC1 signaling. We determined that
TUFT1 promoted perinuclear lysosomal accumulation
and intracellular vesicular trafﬁcking by binding to
RABGAP1, a GAP for certain Rab GTPases. Our inves-
tigations also highlighted the importance of TUFT1 in
tumor growth and metastasis both in vitro and in vivo.
We also revealed that sensitivity to perifosine, an alkyl-
phospholipid AKT inhibitor, strongly correlated with
expression of TUFT1. Unlike other PI3K-AKT inhibitors,
perifosine acts at lipid rafts and inhibited lysosomal
accumulation and mTORC1 signaling. These ﬁndings
implicate that TUFT1 could be a promising therapeutic
target or a biomarker for tumor progression.
Results
TUFT1 is a poor prognostic factor in various cancers
Thyroid transcription factor-1 (TTF-1, also known as
NKX2-1), which is mainly found in thyroid and lung, is a
prognostic indicator of non-small-cell lung cancer24. By
analyzing data from chromatin immunoprecipitation-
based sequencing using antibodies against TTF-1 and
SMAD325, we identiﬁed TUFT1 as a direct target of
transforming growth factor β (TGF-β) which was
inhibited by TTF-1 in NCI-H441 lung adenocarcinoma
cells. Based on a public meta-analysis data, we found that
high TUFT1 expression was correlated with poor prog-
nosis in lung (Fig. 1a), breast (Supplementary Figure S1A)
and gastric cancer (Supplementary Figure S1B) patients26,
27. Particularly in the patients with stage I lung adeno-
carcinoma, TUFT1 expression was more signiﬁcantly
associated with poor prognosis (Fig. 1a).
We observed high expression of TUFT1 in TTF-1-
negative A549 lung adenocarcinoma cells compared to
TTF-1-positive NCI-H441 cells (Supplementary Fig-
ure S1C); furthermore, TUFT1 expression was strongly
induced by TGF-β and the protein was located mainly in
the cytoplasm (Fig. 1b and Supplementary Figure S1D).
To determine whether the induction of TUFT1 by TGF-β
is Smad-dependent, we depleted Smad4 in A549 cells and
examined mRNA expression. Knockdown of Smad4
inhibited the expression of TUFT1, suggesting that TGF-β
stimulates the expression of TUFT1 in a Smad-dependent
manner (Supplementary Figure S1E). Phalloidin staining
revealed morphological change in TUFT1-silenced cells
(Fig. 1c). TGF-β promotes epithelial-mesenchymal tran-
sition (EMT) which is accompanied by increased inva-
siveness of cancer cells, including A549 cells28. However,
the expression of the EMT markers CDH1 (which
encodes E-cadherin), SNAI1 (which encodes SNAIL), and
FN1 (which encodes ﬁbronectin) were not markedly
affected by TUFT1 knockdown (Supplementary Fig-
ure S1F), suggesting that TUFT1 regulates cellular mor-
phology in an EMT-independent manner.
Knockdown of TUFT1 decreased the motility of A549
cells (Fig. 1d). In addition, analysis of the single cell
tracking experiment revealed that knockdown of TUFT1
decreased the average migration speed of these cells
(Supplementary Figure S1G). TUFT1 depletion also
inhibited cell proliferation (Fig. 1e), whereas knockdown
of TUFT1 did not signiﬁcantly affect the viability of A549
cells (Supplementary Figure S1H). The inhibition of cell
motility and proliferation caused by knockdown of
TUFT1 was rescued by forced expression of wild-type
TUFT1 (Fig. 1d, e). When A549 cells were xenografted
onto nude mice, knockdown of TUFT1 decreased the
tumor volume, and it was rescued by wild-type TUFT1
(Fig. 1f). To further investigate whether TUFT1 also
affects tumor metastasis, nude mice were intracardially
injected with MDA-231-D-luc cells29. Bone metastatic
sites were fewer in number in mice that received MDA-
231-D-luc cells with TUFT1 knockdown (Fig. 1g), while
forced expression of TUFT1 canceled the effect (Supple-
mentary Figure S1I).
Members of the Rho family of small GTPases regulate
subcellular cytoskeletal actin dynamics and cellular
motility30. The total amounts of RhoA, Rac1 and Cdc42
proteins were decreased in A549 cells (Fig. 1h and
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Supplementary Figure S2A and B), and also in MDA-231-
D cells to some extents (Supplementary Figure S2C and
D), upon TUFT1 knockdown without decreases in the
mRNA abundance. Exposure to the proteasome inhibitor
MG132 did not restore the abundance of RhoA and Rac1
(Supplementary Figure S2E), indicating that the decrease
in the abundance of these proteins was not due to
enhanced proteasomal degradation. In addition, knock-
down of TUFT1 led to a decrease in the abundance of
cyclin D1 and cyclin D3, which act as cell cycle regulatory
switch in proliferating cells, without decreasing the
mRNA expression (Fig. 1i and Supplementary
Figure S2F).
We then performed RNA sequencing to comprehen-
sively investigate the effects of knockdown of TUFT1. The
gene set enrichment analysis (GSEA) identiﬁed several
signiﬁcantly enriched gene ontology gene sets in the genes
up-regulated in control siRNA-transfected cells, including
mTORC1 signaling (Supplementary Figure S2G). Because
cyclin D1, cyclin D331, and Rho family members of small
GTPases32 are major targets of mTORC1 at the transla-
tional level, we next focused on mTORC1 signaling.
TUFT1 affects perinuclear accumulation of mTORC1 and
the lysosomes
In response to various physiological stimuli, including
growth factors, energy status and amino acids, mTORC1
regulates multiple types of cellular processes, such as
mRNA translation (Fig. 2a). We found that TUFT1
depletion in A549 cells inhibited insulin-induced phos-
phorylation of 70-kDa ribosomal S6 kinase (S6K1), a
downstream effector of mTORC1 signaling, without
decreasing upstream AKT phosphorylation (Fig. 2b). The
results also indicated that knockdown of TUFT1 partially
increased the amount of phosphorylated AKT in A549
cells, possibly by a feedback regulation33. S6K1 phos-
phorylation in response to stimulation with nutrients was
also decreased in MDA-231-D cells (Supplementary Fig-
ure S3A). To determine the physiological functions of
TUFT1 in vivo, we established Tuft1 mutant mice har-
boring a gene trap allele, Tuft1tm1a(KOMP)Wtsi34. Surpris-
ingly, all Tuft1 homozygous mutant mice died within
hours postnatally, indicating the importance of TUFT1 in
mammalian development. We therefore generated pri-
mary MEF cells lacking Tuft1. Consistent with our earlier
results, phosphorylation of S6K1 was lower in Tuft1
mutant MEF cells than in wild-type MEF cells (Fig. 2c).
We then examined the effect of TUFT1 on mTORC1
recruitment to the lysosomal surface. In cells with TUFT1
knockdown, both mTOR and the lysosomes were diffusely
located in the cytoplasm even after stimulation with
amino acids (Fig. 2d). Electron microscopy analysis also
indicated an inhibition of perinuclear accumulation of
electron-dense organelles, which comprise lysosomes and
other lysosome-related organelles, in TUFT1-depleted
cells (Fig. 2e). Amino acids activate mTORC1 through
heterodimers of the Rag subfamily of small GTPases35. To
assess the involvement of TUFT1 in amino acid signaling,
we utilized MKN45 human gastric cancer cells, in which
the NPRL3 gene is homozygously deleted, and Kato III as
control human gastric cancer cells (Supplementary Fig-
ure S3B). NPRL3 is a component of the GATOR1 com-
plex which displays GAP activity for RagA/B;
mTORC1 signaling was therefore constitutively activated
and mTORC1 was localized at the lysosomes in MKN45
cells irrespective of amino acid stimulation36. We
observed consistent results concerning the activation of
mTORC1 signal in the starved MKN45 cells, and
knockdown of TUFT1 in MKN45 cells decreased the
phosphorylation of S6K1 and S6 protein (Fig. 2f). In
addition, we found that amino acid stimulation para-
doxically reduced the phosphorylation of S6K1 and its
target S6, through an unknown mechanism in our
experimental condition in MKN45 cells. Knockdown of
TUFT1 also caused diffuse localization of mTOR and the
lysosomes in these cells (Fig. 2g). In contrast, amino acid
stimulation increased the phosphorylation of S6K1 in
Kato III cells (Supplementary Figure S3C), and the effect
of amino acids was abolished in TUFT1-silenced Kato III
cells. The eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1) is another well-characterized
mTORC1 target. We conﬁrmed depletion of TUFT1
inhibited phosphorylation of 4E-BP1 induced by amino
acid stimulation in Kato III cells (Supplementary Fig-
ure S3C). Translocation of endogenous mTOR to the
lysosomal surface was then examined by an in situ
proximity ligation assay (PLA), an immunoassay that
enables detection of proximity between two proteins. PLA
signals between the antibodies for mTOR and LAMP2
were detected both in control cells and cells with TUFT1
knockdown (Fig. 2h), indicating close proximity between
mTOR and LAMP2. These results show that TUFT1
targets mTORC1 signaling, independently of Rag
signaling-induced recruitment of mTORC1 to the
lysosomes.
TUFT1 controls the network of multiple cellular
compartments
Our data raised the possibility that TUFT1 regulated
lysosomal positioning, which may determine the sur-
roundings of the lysosomes and mTORC1 activity. To
investigate whether lysosomal dispersion affected lysoso-
mal functions, we analyzed the turnover rate of epidermal
growth factor receptor (EGFR) after EGF stimulation.
However, immunoblot analysis revealed that there was
almost no change in the degradation rate of EGFR in
TUFT1 siRNA-treated cells (Supplementary Figure S4A).
Moreover, depletion of TUFT1 did not affect lysosomal
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acidiﬁcation as assessed by LysoTracker staining intensity
(Supplementary Figure S4B), or lysosomal aspartic pro-
tease cathepsin D processing (Supplementary Figure S4C).
Collectively, these results suggested that depletion of
TUFT1 changed lysosomal positioning but did not reduce
lysosomal function.
We next investigated the involvement of TUFT1 in
positioning of non-lysosomal cellular compartments and
vesicular trafﬁcking. Similar to LAMP2, the early
endosomal marker EEA1 was localized diffusely
throughout the cytoplasm in TUFT1-deﬁcient cells
(Fig. 3a). In addition, the distribution of Alexa594-
conjugated transferrin after the endocytosis was
observed at more peripheral regions in TUFT1-depleted
cells (Fig. 3b). We then tested for recycling defects in
these cells. Although TUFT1 depletion did not affect
recycling efﬁciency as detected by a loss of ﬂuorescence
(Fig. 3c), the subcellular components containing
Fig. 2 (See legend on next page.)
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ﬂuorescence-labeled transferrin were mislocalized. On the
basis of these ﬁndings, we hypothesized that knockdown
of TUFT1 resulted in altered positioning of cellular
compartments and vesicular trafﬁcking that affected
mTORC1 signaling.
Distribution and dynamics of cellular compartments
determine mTORC1 activity
Our present ﬁndings suggested the possibility that
TUFT1 regulates positioning of cellular compartments,
vesicular trafﬁcking and mTORC1 signaling by altering
the actin cytoskeletal organization (Fig. 1c). We then
disrupted the actin cytoskeleton with cytochalasin D
(Supplementary Figure S5A) and determined its effects on
lysosomal localization and mTORC1 activation. As pre-
viously reported37, treatment with cytochalasin D had
little effect on subcellular localization of mTOR and the
lysosomes (Supplementary Figure S5B). Cytochalasin D
did not affect phosphorylation of S6K1, S6 or 4E-BP1
(Supplementary Figure S5C). These results suggest that
TUFT1 regulates mTORC1 signaling activity in a RhoA-
actin-independent manner.
We then manipulated retrograde transport with the
cytoplasmic dynein inhibitors ciliobrevin D and erythro-
9-(2-hydroxy-3-nonyl) adenine (EHNA). We found that
these inhibitors caused mislocalization of early endo-
somes, the localization of which is regulated by dynein
activity38 (Supplementary Figure S5D). As previously
described39, the dynein inhibitors disrupted the phos-
phorylation of S6K1 after nutrient treatment without
altering that of AKT (Fig. 4a). In addition, the dynein
inhibitors caused dispersion of the lysosomes and mTOR,
similar to TUFT1 depletion (Fig. 4b). In situ PLA assay
using antibodies for mTOR and LAMP2 indicated that
ciliobrevin D did not disrupt the colocalization of mTOR
and the lysosomes (Supplementary Figure S5E). In
MKN45 cells which have constitutively active RagA/B,
these inhibitors also caused mTORC1 inactivation (Sup-
plementary Figure S5F). In addition, overexpression of
Kif5b, which is required for normal distribution of mul-
tiple organelles including lysosomes40, caused mis-
localization of the lysosomes (Supplementary Figure S5G)
and inhibited S6K1 phosphorylation (Supplementary
Figure S5H). These results suggested that dynein-
regulated vesicular trafﬁcking was necessary for
mTORC1 activity independently of Rag GTPases and
PI3K-AKT signaling.
We next examined whether perinuclear clustering of
the lysosomes affected mTORC1 signaling by utilizing
Rab7a. We used Rab7a and its constitutively active (CA)
mutant (Q67L), which was shown to cause a tight clus-
tering of the lysosomes to the perinuclear region41.
Overexpression of CA forms of Rab7a showed a weak
effect on S6K1 phosphorylation (Fig. 4c) in TUFT1-
depleted cells, indicating that the position of the lysoso-
mal compartment partially affected the mTORC1 activity.
The present ﬁndings also suggested that the effect of
TUFT1 depletion on mTOR signaling is mediated by
some other mechanisms independent of the lysosomal
localization.
TUFT1 interacts with RABGAP1, a GAP for certain Rab
GTPases
By searching BioPlex, a human protein interactome
database in HEK293T cells42, we identiﬁed an interaction
between TUFT1 and RABGAP1 (also known as TBC1D11
or GAPCenA), which belongs to the group of TBC
(TRE2-BUB2-CDC16) domain proteins. The physiological
functions of RABGAP1 are poorly understood. We found
that exogenously expressed RABGAP1 and TUFT1 co-
(see ﬁgure on previous page)
Fig. 2 TUFT1 controls mTORC1 signaling and affects lysosomal positioning. a Schematic model of the mTORC1 activation pathway. b A549
cells treated with indicated siRNAs were serum starved for 24 h before stimulation with or without insulin (10 µg/mL) for 3 h. Cell lysates were
analyzed by immunoblotting. Values in the panel show the amount of phosphorylated protein relative to the total amount of the protein, which
were quantiﬁed by ImageJ. Results are representative of three independent experiments. c Cell lysates of wild type (+/+) and Tuft1−/− MEFs (2 clones
for each genotype) were starved (3 h) or starved and restimulated (10 min) with nutrients. Cell lysates were analyzed by immunoblotting. The amount
of phosphorylated protein was quantiﬁed as in b. Results are representative of two independent experiments. d A549 cells transfected with indicated
siRNAs were starved (3 h) and restimulated (10 min) with amino acids (a.a.). Proteins were coimmunostained with LAMP2 (red) and mTOR (green)
antibodies. Merged ﬁgures are shown in the bottom panels. Images are representative of two independent experiments. Scale bar, 10 μm. e A549
cells were treated with siRNAs as indicated. Electron-dense lysosome-like organelle was observed by electron microscopy. The lower graph show the
quantiﬁcation of the average distance between the centroid of the nucleus and the lysosome-like organelles. Images are representative of three
independent experiments. Scale bars, 2 μm. **P < 0.01. f MKN45 cells transfected with indicated siRNAs were starved (3 h) or starved and restimulated
(10 min) with amino acids (a.a.). Cell lysates were analyzed by immunoblotting. Results are representative of two independent experiments. The
relative amount of phosphorylated protein was quantiﬁed as in b. Note that we consistently observed amino acid stimulation paradoxically reduces
the phosphorylation of S6K1 but not S6 in MKN45 cells. It is possible that some differences in the composition of dialyzed serum affect the
phosphorylation of S6K1. g MKN45 cells were starved of amino acids for 3 h, and cells were stained with antibodies as indicated. Images are
representative of two independent experiments. Scale bar, 10 μm. h A549 cells were treated as in d. Proximity of mTOR to the lysosome was detected
by in situ PLA using mTOR and LAMP2 antibodies. Cell nuclei were counter-stained by DAPI. Images are representative of three independent
experiments. Scale bar, 10 μm.
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immunoprecipitated in HEK293T cells (Supplementary
Figure S6A), and endogenous TUFT1 and RABGAP1 in
A549 cells also co-immunoprecipitated (Fig. 5a and
Supplementary Figure S6B). In addition, to test whether
TUFT1 directly interacts with RABGAP1, we performed
GST pull-down assays using recombinant proteins, and
found that TUFT1 speciﬁcally interacted with RABGAP1
in vitro (Fig. 5b). Compared to control A549 and MDA-
231-D cells, those depleted of RABGAP1 showed reduced
mTORC1 signaling (Fig. 5c and Supplementary
Fig. 3 TUFT1 downregulation causes dysregulation of intracellular compartment positioning and vesicular trafﬁcking. a A549 cells that
were starved (3 h) and restimulated (10 min) with nutrients were coimmunostained with antibodies for EEA1 (red) and mTOR (green). Images are
representative of two independent experiments. Scale bar, 10 μm. b A549 cells transfected with the indicated siRNAs were serum starved for 1 h and
incubated with Alexa594-conjugated transferrin (50 μg/mL) at 37 °C for the indicated time periods. Representative ﬁelds are shown in the left panel.
Images are representative of two independent experiments. Scale bar, 10 μm. In the right panel, the internalized transferrin ﬂuorescence intensity is
shown. Results are means ± s.d. of two independent experiments. c A549 cells transfected with the indicated siRNAs were serum starved for 1 h and
pulsed with Alexa594-conjugated transferrin (50 μg/mL) at 37 °C for 15 min. Cells were ﬁxed at the indicated time points. Representative ﬁelds are
shown in the left panel. Images are representative of two independent experiments. Scale bar, 10 μm. In the right panel, the amount of transferrin in
the cells was quantiﬁed using ImageJ software. Results are means ± s.d. of two independent experiments.
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Figure S6C). Moreover, the lysosomes (Fig. 5d) and early
endosomes (Supplementary Figure S6D) were dispersed
in cells transfected with RABGAP1 siRNAs. In addition,
PLAs using mTOR-LAMP2 antibodies demonstrated that
depletion of RABGAP1 did not disrupt nutrient-mediated
mTORC1 translocation to the lysosomes (Supplementary
Figure S6E).
Rab GAPs inactivate their target Rab GTPases by con-
verting them from the GTP-bound to the GDP-bound
states. To determine whether the effect of RABGAP1 is
GAP activity dependent, we established A549 cells stably
expressing either control (GFP), wild-type RABGAP1
(RABGAP1-WT) or GAP activity-deﬁcient RABGAP1
mutant (R612A)43, and performed rescue experiments
(Supplementary Figure S6F). The result showed that only
RABGAP1-WT could rescue the knockdown phenotype,
indicating that GAP activity of RABGAP1 is required for
mTORC1 activity.
RABGAP1 stimulates the GTPase activity of several Rab
proteins, including Rab4, Rab6, Rab11 and Rab3644–46.
Among them, we conﬁrmed that wild-type and CA forms
(Q182L) of Rab36, but not the dominant negative (DN)
form (T137N), interacted with RABGAP1 (Supplemen-
tary Figure S6G). In addition, overexpression of the CA-
form of Rab36 partially suppressed the phosphorylation of
S6K1 (Supplementary Figure S6H) in HEK293T cells,
suggesting that active Rab36 regulated
mTORC1 signaling. Effect of TUFT1 on RABGAP1
activity was also evaluated. Although our ﬁndings sug-
gested that the substrate of RABGAP1 is not limited to
Rab36 for regulation of mTORC1 activity, the result
suggested that TUFT1 up-regulated GAP activity of
RABGAP1 (Supplementary Figure S6I). TUFT1 therefore
coordinates with RABGAP1 to control the dynamics of
vesicular trafﬁcking and mTORC1 signaling by regulating
some Rab GTPases including Rab36 or some other
molecules (Fig. 5e).
TUFT1 expression is useful for estimating sensitivity of
perifosine
To address the potential of TUFT1 expression and
related intracellular compartment positioning and vesi-
cular trafﬁcking as a molecular target of cancer treatment,
we examined correlations between drug action and
TUFT1 expression obtained from the data provided by
Cancer Cell Line Encyclopedia (CCLE)47 and our pub-
lished database of drug sensitivity across a panel of 39
human cancer cell lines (JFCR39)48, 49. We performed
correlation analysis using conventional anti-cancer drugs
as well as PI3K-AKT-mTOR pathway inhibitors. We
found a signiﬁcant sensitivity to perifosine, which nega-
tively correlated with TUFT1 expression in the cell line
panel (Fig. 6a and Supplementary information, Table S1).
Perifosine, an alkylphospholipid PI3K-AKT inhibitor, is
an anti-tumor compound that alters the composition of
lipid rafts of the plasma membrane, and has been sub-
jected to phase III trials for colorectal cancer and multiple
myeloma. However, the mechanism of action of perifosine
has not been fully elucidated due to its wide range of
actions.
We then evaluated the effect of perifosine on lysosomal
positioning, one of the points of action of TUFT1. A549
cells were treated with perifosine, its analog edelfosine,
the PI3K inhibitor wortmannin or the AKT inhibitor MK-
Fig. 4 Dysregulation of vesicular trafﬁcking leads to mTORC1 inactivation. a A549 cells were starved (2 h), incubated with ciliobrevin D (50 µM)
or EHNA (500 µM) for 1 h, and restimulated (10 min) with nutrients. Cell lysates were collected for immunoblotting. The relative amount of
phosphorylated protein was quantiﬁed as in Fig. 2b. Results are representative of two independent experiments. b A549 cells were treated as in a.
Cells were immunostained with antibodies for LAMP2 (red) and mTOR (green). Merged ﬁgures are shown in the bottom panels. Images are
representative of two independent experiments. Scale bar, 10 μm. c A549 cells transfected with indicated siRNAs and Rab7a expression plasmids
were starved (3 h) and restimulated with nutrients (10 min). Cell lysates were analyzed by immunoblotting. The relative amount of phosphorylated
protein was quantiﬁed as in Fig. 2b. Results are representative of two independent experiments. CA, constitutively active form.
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2206; these drugs inhibited AKT and S6K1 phosphoryla-
tion (Supplementary Figure S7A). Under these conditions,
perifosine and edelfosine totally disrupted mTOR and
lysosomal accumulation, while wortmannin or MK-2206
failed to do so (Fig. 6b). Perifosine and edelfosine also
caused early endosomal dispersion (Fig. 6c), indicating
that perifosine targeted the vesicular trafﬁcking system.
Next, we evaluated the effects of TUFT1 overexpression
on the localization of the lysosomes, and found that
overexpression of TUFT1 reduced the sensitivity of A549
cells to perifosine (Supplementary Figure S7B). In addi-
tion, we compared the sensitivity of A549 (high
Fig. 5 RABGAP1 interacts with TUFT1 and regulates lysosomal positioning and mTORC1 signaling. a Lysates of A549 cells transfected with the
indicated siRNAs were subjected to immunoprecipitation using HA or TUFT1 antibodies. Immunoprecipitates and 3% input extracts were
immunoblotted with the indicated antibodies. Results are representative of two independent experiments. b GST pull-down assays were performed
with GST-10xHis-TUFT1, negative control GST, and recombinant RABGAP1. Speciﬁc interaction of these proteins was detected by immunoblotting.
The lower panel demonstrates the comparable GST fusion protein loading on the lanes. CBB, Coomassie Brilliant Blue staining. c A549 cells
transfected with the indicated siRNAs were starved (3 h) or starved and restimulated (10 min) with nutrients. Cell lysates were analyzed by
immunoblotting. The relative amount of phosphorylated protein was quantiﬁed as in Fig. 2b. Results are representative of two independent
experiments. d A549 cells transfected with the indicated siRNAs were starved (3 h) and restimulated (10 min) with nutrients, then immunostained
with antibodies for LAMP2 (red) and mTOR (green). The merged images are presented in the bottom row. Images are representative of two
independent experiments. Scale bar, 10 μm. e TUFT1 modulates lysosomal positioning, vesicular trafﬁcking and mTORC1 signaling through its
interactions with RABGAP1. A working model illustrating the role of TUFT1-RABGAP1 in lysosomal positioning, vesicular trafﬁcking and mTORC1
activation.
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expression of TUFT1) and NCI-H460 (low expression
of TUFT1) cancer cells to perifosine in terms of the
distribution of mTORC1 and lysosomes. Calculated GI50
(50% growth inhibition) of perifosine was 4.06 μM (NCI-
H460) and 15.3 µM (A549) (Fig. 6a). Consistent with
the above ﬁndings, A549 cells were more resistant
to perifosine in terms of mTORC1 and lysosomal trans-
location than NCI-H460 cells (Supplementary Figure S7C
and D). Although perifosine inhibited the phosphoryla-
tion of both AKT and S6K1, perifosine inhibited
phosphorylation of S6K1 at lower concentrations
than that of AKT in NCI-H460 cells (Fig. 6d). These
results indicated the utility of perifosine as an inhibitor of
mTORC1 signaling, which inhibited both AKT and
mTOR activities.
Discussion
The present study identiﬁed TUFT1 as a factor asso-
ciated with poor prognosis in several types of cancers. We
also showed that this protein regulates tumor growth and
metastasis in vitro and in vivo. Our results here showed
that TUFT1, which likely acts as an adaptor or an effector
for RABGAP1, regulated lysosomal positioning and vesi-
cular trafﬁcking. The vesicular trafﬁcking network is
extensively integrated into various signaling pathways.
Among them, the results of RNA sequencing and other
in vitro experiments indicated that TUFT1 is involved in
mTORC1 signaling.
Normally controlled positioning of intracellular com-
partments and vesicular trafﬁcking have been suggested to
be required for mTORC1 activation. RNAi screening
Fig. 6 Perifosine targets vesicular trafﬁcking and mTORC1 signaling. a Relationship between TUFT1 expression and perifosine sensitivity. The
Pearson correlation coefﬁcient (r) and p-value (P) are shown. Twenty-seven cells, of which we obtained both TUFT1 expression proﬁles from CCLE and
50% growth inhibition (GI50) values of perifosine, were analyzed. b A549 cells were treated with wortmannin (2 μM), MK-2206 (2 μM), perifosine (20
μM) or edelfosine (10 μM). Cells were starved (2 h) in the presence of the indicated inhibitors and with LysoTracker Red (DND-99) for an additional 1 h.
Cells were then restimulated with nutrients (10 min). Proteins were immunostained with antibody for mTOR. Images are representative of three
independent experiments. Scale bar, 10 μm. c A549 cells were starved (3 h) in the presence of the indicated inhibitors and restimulated (10 min) with
nutrients. Cells were ﬁxed and immunostained with EEA1 (red) and mTOR (green) antibodies. Merged ﬁgures are shown. Scale bar, 10 μm. Images are
representative of two independent experiments. d NCI-H460 cells were starved (3 h) or starved and restimulated (10 min) with nutrients in the
absence or presence of perifosine at indicated concentrations. Cell lysates were subjected to immunoblot analysis. The relative amount of
phosphorylated protein was quantiﬁed as in Fig. 2b. Results are representative of three independent experiments. Calculated IC50 values are shown
in the bottom table.
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showed that knockdown of several Rab GTPases decrea-
ses phosphorylation of Drosophila S6K in Drosophila S2
cells17. Overexpression of Rab5 inhibits
mTORC1 signaling and mislocalization of mTOR to
enlarged, swollen vacuolar structures50. Knockdown of
Rab12 activates mTORC1 signaling by affecting cell sur-
face abundance of the amino acid transporter PAT451.
Consistently, disruption of the vesicular trafﬁcking system
by dynein inhibitors inhibited mTORC1 activation, sug-
gesting that cycling of intact Rab GTPases and their cel-
lular trafﬁcking are required for mTORC1 activation.
Dynein-dependent and Rab-dependent intracellular
compartment positioning could play an important role in
mTORC1 signaling. The relationship between lysosomal
positioning in cells and mTORC1 activity is controversial;
lysosomal positioning to the cell periphery has been
reported to enhance mTORC1 activity in HeLa cells15,
whereas perinuclear accumulation of lysosomes and
mTORC1 hyper-activation were observed in a cellular
model of Huntington’s disease16. We here showed that
the disturbance of the cytoskeletal motor activity by
overexpression of Kif5b, which reduced the perinuclear
accumulation of the lysosomes, caused inactivation of
mTORC1 in A549 cells40. These results appear to support
the importance of perinuclear accumulation of lysosomes
for mTORC1 activity. However, overexpression of Rab7a-
CA, which triggered the accumulation of lysosomes to the
perinuclear region41, could only partially rescue the
knockdown effect of TUFT1. The present ﬁndings
therefore suggest that TUFT1-RABGAP1 regulates
mTORC1 signaling by maintaining normal vesicular
trafﬁcking, possibly in part by accumulating the lysosomes
to perinuclear region, although some other mechanisms
may be involved in this phenomenon.
We identiﬁed RABGAP1, which is a GAP for Rab
GTPases, as a binding partner for TUFT1. It was also
conﬁrmed that GAP activity of RABGAP1 is required for
mTORC1 activity. RABGAP1 reportedly targets Rab4,
Rab6, Rab11, and Rab3644, 45. Among them, Rab36 has
been identiﬁed as a candidate target of RABGAP1 in the
present study. In addition, the presence of TUFT1 could
strengthen the GAP activity of RABGAP1 on Rab36.
Although Rab36 does not appear to be the only target of
RABGAP1-TUFT1 for the regulation of
mTORC1 signaling, these results regarding Rab36 provide
important insights into the mechanism of TUFT1 func-
tion through RABGAP1 and target Rab GTPases,
including Rab36.
Vesicular trafﬁcking is involved in various cellular
functions, such as cell differentiation, transformation,
cytoskeleton formation, and invasion52. The expression of
some Rab GTPase-encoding genes are changed in several
human cancers53. Dysfunction of vesicular trafﬁcking is
thus considered to be involved in cancer progression, but
its mechanisms remain unclear. We showed here that
depletion of TUFT1 or RABGAP1 alleviated the accu-
mulation of transport vesicles and lysosomes, which led to
mTORC1 inactivation and tumor regression in A549 lung
adenocarcinoma cells. In addition, treatment with dynein
inhibitors also suppressed mTORC1 activity, indicating
that these procedures could recover normal vesicular
trafﬁcking patterns in cancer cells. Regulation of
mTORC1 signaling by TUFT1-RABGAP1 may thus be a
factor that links vesicular trafﬁcking and tumor progres-
sion. These ﬁndings suggest that regulation of trafﬁcking
system may be a promising target for cancer therapy.
The PI3K-AKT-mTOR signaling pathway is frequently
activated in cancers54, suggesting mTOR as a promising
target for cancer therapy. However, drugs that target the
PI3K-AKT-mTOR signaling pathway have exhibited lim-
ited efﬁcacy. Our drug sensitivity test indicated that the
effect of perifosine, an alkylphospholipid PI3K-AKT
inhibitor, correlated with TUFT1 expression. Unlike
other AKT inhibitors, perifosine directly binds the PH
domain of AKT, preventing its translocation to lipid rafts
of the plasma membrane, which serve as scaffolds for
important signal transduction components55. In addition,
our results suggested a mechanism of action of perifosine
that is related to TUFT1. Perifosine inhibited mTORC1
activation by affecting lysosomal positioning and sub-
cellular vesicular trafﬁcking. In addition, TUFT1-
mediated vesicular trafﬁcking may be involved in the
mechanisms in the generation of drug resistance. Zhou
and colleagues described a role of TUFT1 in the metas-
tasis of pancreatic cancer cells by increasing hypoxia-
inducible factor-1-Snail signaling which promotes EMT22.
We did not detect changes in EMT markers under our
experimental conditions; however, TUFT1 may have dif-
ferent functions in some contexts through the regulation
of vesicular trafﬁcking. Thus, further research may posi-
tion TUFT1 as a biomarker or as a therapeutic target for
various cancers.
Materials and methods
Cell culture
A549 cells were from Cell Resource Center for Biome-
dical Research, Institute of Development, Aging, and
Cancer, Tohoku University. A549, HEK293T, MDA-231-
D (a highly metastatic variant of MDA-MB-231)29, and
MEF cells were cultured in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM #11965; Thermo Fisher Scientiﬁc)
supplemented with 10% fetal bovine serum (FBS
#SH30910.03; Thermo Fisher Scientiﬁc), 100 U/mL
penicillin G, and 100 µg/mL streptomycin. NCI-H441 and
MKN45 cells were maintained in Roswell Park Memorial
Institute medium 1640 (RPMI 1640 #11875; Thermo
Fisher Scientiﬁc) supplemented with 10% FBS, 100 U/mL
penicillin G, and 100 µg/mL streptomycin. NCI-H460-Luc
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cells were obtained from JCRB Cell Bank and maintained
in RPMI 1640 supplemented with 15% FBS, 0.023 IU/mL
insulin, 100 U/mL penicillin G, and 100 µg/mL strepto-
mycin. Cells were grown in a humidiﬁed atmosphere with
5% CO2 at 37 °C. Mycoplasma contamination was routi-
nely checked by e-Myco VALiD Mycoplasma PCR
detection kit (CosmoBio).
Reagents and antibodies
Recombinant TGF-β (TGF-β3) was purchased from
R&D Systems. Fluorescein Isothiocyanate Labeled Phal-
loidin (#P5282), LysoTracker Red (DND-99) (#L7528),
Alexa-488 conjugated transferrin (#T13342), perifosine
(#SML0612), and edelfosine (#SML0332) were obtained
from Sigma-Aldrich. MK-2206 (#ENZ-CHM164) was
from Enzo Life Sciences. Cytochalasin D (#037–17561)
was from Wako Pure Chemical Industries. Ciliobrevin D
(#250401) was obtained from Merck Millipore. EHNA
(#13352) was purchased from Cayman Chemical.
Antibodies against the following proteins were pur-
chased from Cell Signaling Technology: mTOR (#2983),
pS6K1 (Thr389) (#9234), S6K1 (#9202), pAKT (Thr308)
(#2965), AKT (#9272), pS6 (Ser240/244) (#2215), S6
(#2217), p4E-BP1 (Ser65) (#9451), 4E-BP1 (#9644) and
pERK1 and 2 (pERK1/2) (Thr202/Tyr204) (#9101). Anti-
bodies against TUFT1 (#sc-47536), cyclin D1 (#sc-718),
cyclin D3 (#sc-182), RhoA (#sc-418) and cathepsin D
(#sc-6487) were obtained from Santa Cruz Biotechnology.
Antibodies against LAMP2 (#ab25631) and RABGAP1
(#ab153992) were purchased from Abcam. HDAC1
(#2E10), ERK1 and 2 (#05–1152) and EGFR (#05–101)
antibodies were obtained from Merck Millipore. Antibody
for EEA1 (#610457) was purchased from BD Biosciences.
Antibody for c-Myc (#017–21871) was obtained from
Wako Pure Chemical Industries. Antibodies against
FLAG (M2; #F3165 and #F1804) and α-tubulin (#T6199)
were obtained from Sigma-Aldrich. Antibody for Cdc42
(#ACD03) was obtained from Cytoskeleton.
Plasmids
Plasmids encoding human TUFT1, RABGAP1, Rab36,
and dog Rab7a were constructed by PCR ampliﬁcation.
The fragments were subcloned into pcDEF3-FLAG vector
(TUFT1), pGEX-6P-1 vector (TUFT1), pcDNA3-FLAG
vector (Kif5b and Rab7a), or pcDNA3-Myc vector
(Rab36). Mutant Rab7a, RABGAP1 and Rab36 were
generated by PCR mutagenesis. All cDNAs constructed
were veriﬁed by sequencing. Plasmids encoding mouse
Kif5b (pKin1B, Addgene plasmid #31604) was a gift from
Dr. Anthony Brown56.
Amino acid starvation and stimulation of cells
Cells were rinsed twice with DMEM with sodium pyr-
uvate, without amino acids (#048–33575; Wako Pure
Chemical Industries) containing 10% dialyzed serum
(#SH30079; GE Healthcare) and incubated for 3 h. Cells
were then stimulated with DMEM (#11965) containing
amino acids and 10% FBS as indicated.
Nutrient starvation and stimulation of cells
Cells were rinsed twice with amino acids (Arg, Leu, and
Lys)-free DMEM (#D9443; Sigma-Aldrich) and incubated
for 3 h. Cells were then stimulated with DMEM (#11965)
containing amino acids and 10% FBS as indicated.
Knockout mouse production
All animal experiments were performed in accordance
with policies of the Animal Ethics Committee of the
University of Tokyo. ES cells harboring Tuft1tm1a(KOMP)
Wtsi allele (EPD0383_4_G08) were obtained from the
International Mouse Phenotype Consortium (http://www.
mousephenotype.org) and cultured in the medium con-
taining 3i components57. C57BL/6N female mice and ICR
mouse strains were used as embryo donors and foster
mothers, respectively. Animals were genotyped using
DNA extracted from tail segments. Wild-type and mutant
alleles were detected by multiplex PCR with the same
reverse primer (WT-R: 5′-CCCTGAGGGACCAGCCA-
CATAGAACAGA-3′) and different forward primers
(mutant allele, Tuft1-F: 5′-TGGTCTGAGCTCGCCAT-
CAGTTTCA-3′; wild-type allele, WT-F: 5′-CTGTTAG-
CATTCTGTCTAAACTTCACCCCA-3′).
Subcutaneous xenograft model
BALB/c nu/nu mice (4 weeks of age) were obtained
from Sankyo Labo Service. Cells (5× 105) were injected
into each mouse. Subcutaneous tumors were measured
externally, and tumor volume was calculated as previously
described58.
In vivo bone metastasis model
Stably transfected MDA-231-D-luc cells (1× 105 cells),
which harbored luciferase, were injected into the left
ventricle of female nude mice. Five weeks after injection,
bone metastatic cells were analyzed by bioluminescence
imaging.
Electron microscopy
A549 cells were transfected with siRNA for TUFT1 or a
negative control siRNA (siNC). For electron microscopic
analysis, cells were treated as previously described59.
Lentivirus production and infection
Lentiviral shRNA expression vectors were generated as
described29. We used the following oligonucleotides
(5′→3′): Human TUFT1 #1, GATCCCCGCTGGT-
CATTCTCTGGCTTACGTGTGCTGTCCGTAAGCCA-
GAGAATGACCAGCTTTTTGGAAAT and CTA
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GATTTCCAAAAAGCTGGTCATTCTCTGGCTTACG
GACAGCACACGTAAGCCAGAGAATGACCAGCGG
G; Human TUFT1 #2: GATCCCCGGATATAAGTA
GCAAGCTTACGTGTGCTGTCCGTAAGCTTGCTAC
TTATATCCTTTTTGGAAAT and CTAGATTTCCAA
AAAGGATATAAGTAGCAAGCTTACGGACAGCACA
CGTAAGCTTGCTACTTATATCCGGG.
Lentiviral expression vectors were obtained from Dr.
Hiroyuki Miyoshi (RIKEN BioResource Center. current
address: Keio University, Tokyo, Japan). shRNAs were
transferred into the lentivirus vector CS-RfA-EG through
the pENTER-4H1 vector. To produce lentivirus,
HEK293FT cells were transfected with the vector con-
structs pCMV-VSV-G-RSV-Rev and pCAG-HIVgp. Virus
was collected, concentrated with the Lenti-X Con-
centrator (Takara Bio), and used to infect A549 cells and
MDA-231-D cells.
RNAi in mammalian cells
RNAi was carried out with the following siRNAs
designed from siDirect (RNAi inc.) (5′→3′): Human
TUFT1#1, GGAUAUAAGUAGCAAGCUUGA and
AAGCUUGCUACUUAUAUCCUC; Human TUFT1#2,
GUAGCCUUUUGCGGAAAAAUU and UUUUUCCG-
CAAAAGGCUACUC; Human mTOR#1, GAUCU-
CAUGGGCUUCGGAACA and UUCCGAAGCCCAU
GAGAUCUU; Human mTOR#2, CCAAUUAUACCC-
GUUCUUUAG and AAAGAACGGGUAUAAUUGGUU;
Human LAMP2#1, GAUAAGGUUGCUUCAGUUAUU
and UAACUGAAGCAACCUUAUCCU; Human
LAMP2#2, GCUCUACUUAGACUCAAUAGC and
UAUUGAGUCUAAGUAGAGCAG; Human RAB-
GAP1#1, GGGAUAUUAACCGAACAUUCC and AAU-
GUUCGGUUAAUAUCCCGG; Human RABGAP1#2,
GACGCAUGUUGGUAGGUCACU and UGACCUAC-
CAACAUGCGUCUA. For human SMAD4 siRNA,
Stealth Select siRNA (HSS106256, UAAG
GCACCUGACCCAAACAUCACC) was used (Thermo
Fisher Scientiﬁc), with Negative Control Med GC Duplex
#2 (12935112, Thermo Fisher Scientiﬁc, sequence not
available) as a control.
siRNAs were transfected into cells using Lipofectamine
RNAiMAX reagent (Thermo Fisher Scientiﬁc) in accor-
dance with the manufacturer’s instructions. The ﬁnal
concentration of siRNA in the culture medium was 10
nM.
Transfection of cDNA
Transient transfection into cells was performed using
Lipofectamine 2000 or Lipofectamine 3000 reagent
(Thermo Fisher Scientiﬁc), as recommended by the
manufacturer’s protocol.
Adenovirus production and infection
Ad-LacZ and Ad-TUFT1 were prepared using pAd/
CMV/V5-DEST vector. The crude adenoviral lysate was
puriﬁed using ViraKit (VIRAPUR). Titration was per-
formed by the Adeno-X Rapid Titer Kit (Clontech).
Immunoblotting
All experiments were done at least twice with similar
results. Cultured cells were rinsed with ice-cold phos-
phate-buffered saline (PBS) and lysed with lysis buffer (1%
NP-40, 150mM NaCl, 20 mM Tris-HCl (pH 7.5), and
cOmplete EDTA-free protease inhibitor (Roche)). After
centrifugation at 15,000 rpm at 4 °C for 10min, protein
concentrations were estimated with the BCA Protein
Assay Kit (Thermo Fisher Scientiﬁc). Total cell lysates
were subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis and transferred to FluoroTrans W
membranes (Pall). Immunoblotting was carried out using
the indicated antibodies, and imaging was performed with
a LAS-4000 lumino-image analyzer (FUJIFILM). Band
intensity was measured using ImageJ 1.50b (National
Institutes of Health).
Immunoprecipitation
Cultured cells were lysed as described above. Immu-
noprecipitation was performed as previously described60.
GST pull-down assay
GST fusion protein of TUFT1 and control GST were
prepared in Escherichia coli. Recombinant RABGAP1 was
obtained from Abcam (#ab161730). The RIPA buffer (50
mM Tris-HCl (pH 8.0), 150mM NaCl, 0.1% SDS, 0.5%
DOC, 1% Triton X-100) was used for the binding assay
between TUFT1 and RABGAP1.
Nuclear/cytoplasmic fractionation
Nuclear/cytoplasmic fractionation of A549 cells was
performed using the NE-PER Nuclear and Cytoplasmic
Extraction Kit (Thermo Fisher Scientiﬁc) in accordance
with the manufacturer’s instructions.
Immunoﬂuorescence microscopy
Cells were seeded in eight-well chamber slides (Thermo
Fisher Scientiﬁc) and cultured or stimulated as described.
Cells were ﬁxed for 15 min in 4% paraformaldehyde in
PBS, permeabilized in PBS containing 0.1% Triton X-100
for 7 min, and blocked in Blocking One (Nacalai Tesque)
for 1 h at room temperature. After rinsing in PBS, slides
were incubated with primary antibodies in Blocking One
for 12–16 h at 4 °C and washed in PBS. Secondary anti-
bodies were diluted in Blocking One and incubated with
the slides for 1 h at room temperature. Chamber slides
were mounted on glass coverslips using VECTASHIELD
Antifade Mounting Medium with DAPI (Vector
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Laboratories). Images were obtained with an FV10i con-
focal laser-scanning microscope (Olympus).
In situ PLA
Cells were cultured, ﬁxed, and permeabilized as
described above. We used the Duolink (Sigma-Aldrich)
kit in accordance with the manufacturer’s protocol.
Fluorescence images were obtained with an FV10i
microscope. Images were collected from single focal
planes.
RNA extraction and qRT–PCR
Quantitative reverese transcriptase–PCR (qRT–PCR)
was previously described61. For mRNA detection, total
RNA was extracted with TriPure Isolation Reagent
(Roche) or with the RNeasy Mini Kit (QIAGEN). First-
strand cDNAs were synthesized using PrimeScript II
reverse transcriptase (Takara Bio). qRT-PCR was per-
formed with the StepOnePlus Real-Time PCR System
(Thermo Fisher Scientiﬁc). All samples were run in
duplicate, and results were averaged and normalized to
the expression of GAPDH (which encodes
glyceraldehyde-3-phosphate dehydrogenase).
Transferrin uptake assay
Cells were starved in serum-free DMEM for 1 h. Then,
cells were incubated with Alexa-488 conjugate transferrin
(50 μg/mL) for the indicated periods at 37 °C. To study
transferrin endocytosis and recycling, cells were incubated
with Alexa-594 transferrin (50 μg/mL), washed with PBS
three times, and then incubated at 37 °C for various
lengths of time. Cells were ﬁxed immediately. Images
were taken with an FV10i confocal laser-scanning
microscope.
Chamber migration assay
The migration assay was performed as described pre-
viously29. Migrated cells were counted as ﬁeld images that
were selected randomly. The average number of cells was
calculated from these images.
Statistical analyses
Comparisons between two samples were performed
with the Welch's t-test for in vitro data, and the Mann-
Whitney-Wilcoxon test (Mann-Whitney U test) for
in vivo data. Comparisons between the multiple experi-
mental groups were made using Turkey-Kramer test for
in vitro data, and Steel-Dwass test for in vivo data. Sta-
tistical analyses were conducted with the R Project for
Statistical Computing (version R-3.3.2). We calculated the
degree of similarity between drug sensitivity and gene
expression using the Pearson correlation coefﬁcient, as
described49.
RNA sequencing
Total RNA was extracted with the RNeasy Mini Kit
(QIAGEN) from siRNA-transfected A549 cells. mRNA
was puriﬁed using the Dynabeads mRNA DIRECT Pur-
iﬁcation Kit (Thermo Fisher Scientiﬁc). Libraries were
prepared using the Ion Total RNA-Seq Kit v2 according
to the manufacturer’s protocol and directionally
sequenced with the Ion Proton using the Ion PI chip v2
and Ion PI IC 200 Kit (Thermo Fisher Scientiﬁc). Reads
were aligned against the human genome (hg19) using
TopHat2. Differential expression was evaluated using the
Cuffdiff function of Cufﬂinks. Raw sequencing data are
available at GEO (GSE99149).
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